cisplatin,nivolumab,atezolizumab,Pembrolizumab
bms,roche,Merck
['mibc', 'nivolumab', 'cisplatin', 'ca,209,274', 'urothelial', 'check,mate,274', '#gu,(-#gui),(-#gunagratinib),(-#guard),(-#gut)', 'thanks', 'cm274', 'imvigor010', 'imvigor,11', 'nivo']
updates on #cm274 by adjuvant nivo vs pcb x1yr in mibc &amp; commentary by dr. heijden #gu23: dfs 22.0mo vs 10.9mo (hr 0.71) pdl1+: 52.6mo vs 8.4mo (hr 0.52) subgroup w no nac, no benefit primarily white men ecog 0-1 await os data other adjuvant io trials (-) 
GU Oncologist | 🇨🇦 GU & NOLA Heme/Onc Alumni | Interested in GU, Immuno Onc & Med Ed | @ASCO Featured Voice | @TwoOncDocs podcast